Halozyme Therapeutics (HALO) Climbs +6.5% Over 30 Days on Strong Fundamentals
Key Takeaways
- HALO trades near $107, up roughly 6.5% over the trailing 30 days and holding close to its 52-week high of $111.15.
- Second-quarter results beat expectations, with total revenue up 48% and royalty revenue up 50% year over year.
- Management raised full-year 2026 guidance, projecting royalty revenue of $1.22 billion to $1.25 billion.
- The ENHANZE platform remains the core growth engine, powered by blockbuster partner products such as DARZALEX, VYVGART Hytrulo, and Phesgo.
- Key watch items include patent litigation with Merck and rising competition from Alteogen's ALT-B4 technology.
Market Snapshot and Valuation
Shares of HALO have settled near $107 after a strong run that began with the company's second-quarter earnings release. The stock sits just below its 52-week high of $111.15 and far above its 52-week low of $61.22, reflecting a sustained re-rating over the past year. With a market capitalization of roughly $12 billion and a beta near 0.88, the stock has exhibited lower volatility than the broader market while delivering substantial capital appreciation.
Institutional investors hold approximately 97.8% of shares outstanding, underscoring heavy professional ownership. Analyst sentiment is broadly constructive, with a consensus "Moderate Buy" rating, though the average 12-month price target of about $91.20 sits below the current share price — a reminder that the stock's recent momentum has outpaced many sell-side targets and that valuation remains a topic of debate. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Model and Competitive Position
Headquartered in San Diego, Halozyme Therapeutics is a biopharmaceutical company focused on drug-delivery technology rather than internal drug discovery. Its flagship ENHANZE platform, based on the proprietary enzyme rHuPH20, temporarily breaks down hyaluronan in the extracellular matrix to enable large-volume biologic therapies to be administered subcutaneously instead of through lengthy intravenous infusions. This approach shortens treatment time, reduces infusion-related reactions, and expands access to community care settings.
ENHANZE underpins ten commercialized products across more than 100 markets and is licensed to major pharmaceutical partners including Roche, Janssen, Pfizer, Bristol Myers Squibb, argenx, AbbVie, Eli Lilly, GSK, and Incyte. Halozyme earns mid-single-digit royalties on partner sales, giving it a high-margin, capital-light business model with adjusted EBITDA margins projected above 65%. The company has also expanded into hyperconcentration technologies through its Hypercon and Surf Bio platforms, and it markets proprietary products such as Hylenex and XYOSTED alongside auto-injector partnerships.
Recent Earnings and Key Developments
The most significant catalyst in recent weeks was second-quarter 2026 results, reported in early August. Total revenue rose 48% year over year to $481 million, while royalty revenue climbed 50% to $308 million. Non-GAAP diluted earnings per share reached $2.28, well above the consensus estimate of $1.79, and adjusted EBITDA grew 46% to $329 million. Management raised its full-year outlook, now guiding to total revenue of $1.835 billion to $1.910 billion and non-GAAP EPS of $8.65 to $9.00.
Growth is being driven by recently launched subcutaneous therapies including OCREVUS, OPDIVO Qvantig, and RYBREVANT, alongside established franchises DARZALEX and VYVGART Hytrulo. Halozyme also continued to sign new deals, adding collaborations with GSK for antibody-drug conjugates, Incyte, Vertex, Oruka, and an undisclosed nucleic-acid partner. The company repurchased roughly $333 million of stock in the quarter as part of a $1 billion buyback authorization, and several analysts raised price targets, including Leerink Partners upgrading the stock to Outperform. From what I see, the royalty momentum here is particularly noteworthy.
On the risk side, Halozyme remains engaged in patent litigation with Merck, with Patent Trial and Appeal Board decisions expected late in September. Separately, Alteogen's ALT-B4 platform — endorsed through agreements with Merck and Novartis — represents a growing competitive challenge to ENHANZE's subcutaneous-delivery franchise.
2026 Outlook and Investor Watch Points
Halozyme's forward trajectory hinges on continued royalty growth from ENHANZE-enabled products. The company projects up to 13 additional ENHANZE programs in clinical development by the end of 2026, with launches beginning around 2029, while its Hypercon platform is expected to initiate Phase 1 studies in the first half of 2027 and contribute launches in the 2030–2031 timeframe.
Investors should monitor several factors in the months ahead: the outcome of patent proceedings with Merck and any related European rulings, the pace of subcutaneous conversion for OPDIVO and OCREVUS, new partnership signings, and whether management sustains its raised 2026 guidance. Competitive pressure from ALT-B4 and the 2029 patent expiration timeline for certain ENHANZE products represent longer-term risks, as does the concentration of royalties among a relatively small number of partner products. Share repurchases and disciplined capital allocation may continue to support the stock, but valuation relative to analyst targets warrants close attention. I’m watching this closely as the patent outcomes could shift the competitive landscape.
Leveraging AI Tools for Deeper Analysis
In my own research process, Tickeron’s Trending AI Robots page has become a useful resource for reviewing automated strategies tied to names like HALO. It surfaces top-performing bots across different timeframes and approaches, allowing me to cross-check signals without relying solely on discretionary calls. This kind of systematic view helps filter noise and complements traditional fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HALO sees MACD Histogram crosses below signal line
HALO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In 23 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HALO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 25 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In 46 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
HALO broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in 269 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 243 of 317 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (89.286) is normal, around the industry mean (26.780). P/E Ratio (33.103) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement